BOSTON — Quality Means Business (QMB Inc.), an emerging leader in AI-driven MedTech software, announced the close of a $2 million seed funding round to launch QualiVerse, its flagship Regulatory Intelligence Engine designed to help medical device innovators achieve compliance, accelerate product development, and scale safely to market. The round was led by The Boston Foundation’s Business Equity Investment Fund and CEI Ventures.
The funding positions QMB as a category-defining company at the intersection of artificial intelligence, regulatory intelligence, and MedTech innovation. QualiVerse leverages AI to transform how medical device manufacturers manage quality, regulatory, and development processes — streamlining compliance and enabling faster, safer innovation cycles.
“QMB is building the category infrastructure that MedTech has been missing,” said Anthony Rust, Fund Manager of the Business Equity Investment Fund. “Michel’s vision is deeply informed by lived experience as both a regulator and SaaS product architect — and this is exactly the kind of entrepreneur we back to redefine industries.”
“We’re excited to support QMB in bringing critical innovation to the MedTech sector,” added Orlando Watkins, Vice President and Chief Program Officer of The Boston Foundation. “QualiVerse represents the type of transformative technology that not only drives business growth but also has the potential to improve patient outcomes on a global scale. This aligns perfectly with our mission to invest in companies that create meaningful economic opportunity while advancing social impact.”
Shannon Bean, Principal at CEI Ventures, said the firm’s investment reflects its commitment to equitable and sustainable job creation. “CEI Ventures is proud to partner with QMB. We’re especially proud that all current and planned jobs at QMB exceed the MIT Living Wage for Norfolk County, aligning with our Good Jobs Framework and commitment to equitable, high-quality employment. QualiVerse is the rare platform that marries technical sophistication with impact at scale — accelerating safer devices to patients worldwide.”
“Quality and regulatory are the unsung heroes of medical innovation — they safeguard lives while too often operating in the shadows,” said Michel Moravia, Chairman and CEO of QMB. “With QualiVerse, we’re giving these teams the intelligent platform they deserve — a system that makes compliance not a bottleneck, but a catalyst for innovation. As both a MedTech regulatory veteran and product leader in enterprise SaaS, I know firsthand the cost of delay and the urgency of getting this right.”
Building on early enterprise traction and pilot interest from major device manufacturers, QMB plans to use the funding to expand engineering, enhance data integrations, and advance RegTech-as-Infrastructure pilot programs with MedTech partners in late 2025.
